NEW YORK (GenomeWeb News) — Qiagen today said that federal regulators have cleared its planned acquisition of Digene.
 
The company said the Hart-Scott-Rodino antitrust deadline passed on midnight yesterday without a hitch, enabling the shop to buy Digene for $1.6 billion.
 
The deal is subject to the tender of a majority of Digene's common stock on a fully diluted basis before 11:59 p.m. EST on July 20, unless the offer is extended, as well as approval by Qiagen’s shareholders, among other conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.